WO1995011004A1 - A personal care composition - Google Patents
A personal care composition Download PDFInfo
- Publication number
- WO1995011004A1 WO1995011004A1 PCT/EP1994/003432 EP9403432W WO9511004A1 WO 1995011004 A1 WO1995011004 A1 WO 1995011004A1 EP 9403432 W EP9403432 W EP 9403432W WO 9511004 A1 WO9511004 A1 WO 9511004A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- formula
- carbon atoms
- group
- accordance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/45—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/596—Mixtures of surface active compounds
Definitions
- the present invention relates to a personal care composition in liquid or gel form suitable for use as a shower product.
- the composition of the invention imparts an excellent skin feel.
- personal care products like shower creams and shower gels, besides a cleaning effect, also provide a mild and silky feel to the skin both at the time of appli- cation and after the use.
- the products shall also provide a foam of high volume and good texture to facilitate the appli ⁇ cation of the product on the skin e.g. by a sponge.
- clea- ning products for personal care that contain an anionic surfactant and a betaine.
- the betaines may cause irritation in the eyes and have a low contribution to a mild silky skin feel.
- a skin cleaning mousse-forming product is also described in EP-B1-194 097.
- the product contains a nonsoap surfactant such as a sulfonate, a sulfate or a betaine, and a moisturizer.
- a specific skin feel aid is added.
- One object of the present invention is to provide a mild personal care product with a smooth and silky feel at the time of application as well as after the use. Furthermore the level of foam volume shall be high. Another object is to obtain acceptable skin feel and foaming properties without the need of using amphoteric quarternized ammonium compounds, like betaines, and skin feel aids.
- a personal care composition comprising a) a combination of amphoteric compounds containing i) at least one amphoteric compound, which has the formula R ⁇ (CO) n -[N-(CH 2 ) x ] y -N-Q (I) B B wherein R x is a hydrocarbon group of from 15 to 22 carbon atoms, n is 0 or 1, x is 2 or 3, y is an integer of 0 to 4, Q is CH 2 COOM or CH 2 CH 2 COOM, wherein M is hy ⁇ drogen or an ion from the groups of alkali metals, ammonium or substitued ammonium and B is hydrogen, an hydroxyalkyl group with 2-3 carbon atoms or a group Q as defined; ii) at least one amphoteric compound, which has the formula R 2 (CO) n -[N-(CH 2 ) x ] y -N-Q (II
- the component a) is 10-35%, component b) 10-25% and component c) 50-80% by weight based on the total amount of a) , b) and c) .
- the weight ratio between component a) and component c) is suitably from 2:3 to 1:8 and the weight ratio between component b) and component c) is from 1:2 to 1:8.
- the composition contain at least one alkoxylated amide with the formula (III) and at least one alkoxylated amide with the formula (IV) , the weight ratio between the compounds with formula III and the compounds with formula (IV) being from 1:6 to 6:1.
- a blend of these surfactants enables the manufacture of shower products with outstanding performance, especially with regard to after-use skin feel. It is the surfactants alone ' which are responsible for the skin feel and there is no need to add polymeric material or other emollients in order to achieve an exceptional after-use feel.
- the amphoteric compounds with the formulae (I) and (II) also contribute to the cleaning effect of the composition.
- the compounds with formula (I) promote the feel of foam and the after-use feel, while compounds with formula (II) generally promote foaming.
- the alkoxylated amides of formula (IV) increases the volume of foam, while the compounds of formula (III) have a thickening effect in combination with an improved after-use feel and a creamy texture of the foam.
- any expected toxic effects or skin irritaitons due to the presence of the anionic surfactant are essentially lowered depending on the substantial amounts of amphoteric compounds and alkoxylated amides in the composition.
- i and R 2 are preferably aliphatic groups, R x containing 16-20, mainly 18 carbon atoms and R 2 10-14, mainly 12 carbon atoms.
- the groups R ⁇ and R 2 can be both unsaturated and saturated and suitably they are derived from rapeseed oil and coconut oil.
- One class of preferred ampholytic compounds with formu ⁇ lae (I) and (II) are those where x is 3, n is 0, y is 2-3 and B is the group Q.
- Another class of suitable amphoteric compounds with formulae (I) and (II) are those where n is 1, and each B independently of each other hydrogen, a hydroxyalkyl group with 2-3 carbon atoms or the Q group with the proviso that at least one of the B groups is the hydroxyalkyl group. Examples of such compounds are those with the formulae R-C(O)-N-CH 2 CH 2 -N-CH 2 COOM (V) CH 2 CH 2 OH CH 2 COOM and
- composition may also contain other types of amphoteric compounds as well as zwitterionic compounds like betaines.
- Suitable zwitterionic compounds are those with the formula CH 3 R a -N + -(CH 2 ) m COOM (V) CH 3 wherein R a is a hydrocarbyl chain of 7-21 carbon atoms and preferably is an alkyl or alkenyl radical of from 11 to 17 carbon atoms; m is 1 or 2; M is preferably H or sodium ion.
- Preferred alkoxylated amides with the formulae (III) and (IV) are those, where n is a number from 0 to 4, most preferably from 2-3, and R 3 is an acyl group with 16-20, mainly 18 carbon atoms and R- is an acyl group with 10-14, mainly 12 carbon atoms.
- Preferably at least 50 % of all A groups are the ethyleneoxy group, and most preferably both R 5 and A are ethyleneoxy groups.
- the R 3 and R 4 groups are suitably derived from rapeseed oil and coconut oil.
- Anionic surfactants suitable for inclusion in the com- positions are those generally used in personal care products and include alkylsulfates, ethoxylated alkyl sulfates, alkyl polyglucoside sulfates, fatty acid polyglyceride sulfates, fatty acylamido polyoxyethylene sulfate, alkyl glyceryl ether sulfonates, methyl acyl taurates, fatty acyl glycinates, N-acyl glutamates, acyl isethionates, alkyl sulfosuccinates, alpha- sulfonated fatty acids, their salts and/or their esters, alkyl phosphate esters, ethoxylated alkyl phosphate esters, acyl sarcosinates and fatty acid/protein condensates, and mixtures thereof.
- the alkyl and/or acyl groups for these surfactants contain 8-22,
- the sulfate compounds especially the salts of sulfuric acid esters of the reaction product of 1 mole of a higher fatty alcohol with 10-18 carbon atoms and from about 1 to about 5 moles of ethylene oxide, with sodium, ammonium or magnesium being the preferred counterions.
- Particu- lary preferred are the alkyl ether sulfates containing from about 2 to 4 moles of ethylene oxide, such as sodium lauryl dioxyethylene sulfate, sodium lauryl trioxyethylene sulfate.
- the composition of the invention may also contain normally used components, such as preservatives, pearlescent agents, opacifiers, colourants and fragrance. Preservatives may e.g.
- the pearlescent agent may e.g. be Empicol XP40 (Albright & Wilson) .
- Opacifiers may suitably be polymeric substances, such as copolymers of vinyl pyrrolidone and styrene.
- the colourants may e.g. include FDC Yellow and FDC Orange 4.
- the pH of the composition should be within a range of 4.5 to 7.0, and preferably 5.5.
- a pH adjusting agent can be used, such as an organic acid, e.g. citric or lactic acid, or an inorganic acid, e.g. hydrochloric acid.
- compositions were prepared from an anionic surfactant, amphoteric surfactants and amide etoxylates.
- the compounds used are as set forth in the following table.
- R ⁇ is a C 16 _ 18 aliphatic group, x and y is 3, n is 0, and B and Q are
- a quantity of 0.5 g of the formulations was transferred to the arm, and the arm was then rubbed five times initially, and then up to a further twenty times. Each time the volume of foam and the feel of the foam on the skin were recorded.
- the arms were then rinsed with warm water and dried using a clean towel.
- the after-feel was recorded after five minutes. The following results were obtained.
- formulation 3, 6 and 7 in accordance with the invention exhibits advantageous and synergistic effects in comparison with the formulations 1, 2, 4 and 5.
- a shower cream composition based on formulation 7 was compared with three shower products on the commercial market with regard to the volume of foam, feel of foam and after-use feel.
- composition of the shower cream was as follows.
- the pH-value of the shower cream was adjusted to 5.3 by adding citric acid. After this addition the shower cream had an viscosity of 16 000 cps.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94930961A EP0737061A1 (en) | 1993-10-22 | 1994-10-17 | A personal care composition |
JP7511325A JPH09504017A (en) | 1993-10-22 | 1994-10-17 | Personal care composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9303481A SE9303481L (en) | 1993-10-22 | 1993-10-22 | hygiene composition |
SE9303481-7 | 1993-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995011004A1 true WO1995011004A1 (en) | 1995-04-27 |
Family
ID=20391505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/003432 WO1995011004A1 (en) | 1993-10-22 | 1994-10-17 | A personal care composition |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0737061A1 (en) |
JP (1) | JPH09504017A (en) |
SE (1) | SE9303481L (en) |
WO (1) | WO1995011004A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801139A (en) * | 1997-06-05 | 1998-09-01 | Lever Brothers Company, Division Of Conopco, Inc. | Process for making bar compositions comprising novel chelating surfactants |
US5869441A (en) * | 1997-06-05 | 1999-02-09 | Lever Brothers Company, Division Of Conopco, Inc. | Bar compositions comprising novel chelating surfactants |
DE10150410A1 (en) * | 2001-08-10 | 2003-02-27 | Beiersdorf Ag | Cosmetic cleaning preparations based on a combination of sodium laureth sulfate and alkyl polyamphopolycarboxylglycinates |
US8450298B2 (en) | 2008-11-07 | 2013-05-28 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US9006487B2 (en) | 2005-06-15 | 2015-04-14 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
US9181321B2 (en) | 2013-03-14 | 2015-11-10 | Shire Human Genetic Therapies, Inc. | CFTR mRNA compositions and related methods and uses |
US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
US9227917B2 (en) | 2012-08-13 | 2016-01-05 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
US9308281B2 (en) | 2011-06-08 | 2016-04-12 | Shire Human Genetic Therapies, Inc. | MRNA therapy for Fabry disease |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
US9522176B2 (en) | 2013-10-22 | 2016-12-20 | Shire Human Genetic Therapies, Inc. | MRNA therapy for phenylketonuria |
US9629804B2 (en) | 2013-10-22 | 2017-04-25 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger RNA |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
US9850269B2 (en) | 2014-04-25 | 2017-12-26 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US9957499B2 (en) | 2013-03-14 | 2018-05-01 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US10022455B2 (en) | 2014-05-30 | 2018-07-17 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
US10138213B2 (en) | 2014-06-24 | 2018-11-27 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
US10576166B2 (en) | 2009-12-01 | 2020-03-03 | Translate Bio, Inc. | Liver specific delivery of messenger RNA |
US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US11173190B2 (en) | 2017-05-16 | 2021-11-16 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR |
US11224642B2 (en) | 2013-10-22 | 2022-01-18 | Translate Bio, Inc. | MRNA therapy for argininosuccinate synthetase deficiency |
US11253605B2 (en) | 2017-02-27 | 2022-02-22 | Translate Bio, Inc. | Codon-optimized CFTR MRNA |
US11254936B2 (en) | 2012-06-08 | 2022-02-22 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0127580A2 (en) * | 1983-05-31 | 1984-12-05 | Ciba-Geigy Ag | Mixtures of quaternary polymeric ammonium salts and of a ternary surfactant system based on non ionic, anionic and amphoteric surfactants, its preparation and its use in cosmetic compositions |
EP0160507A2 (en) * | 1984-04-25 | 1985-11-06 | Eric Graham Fishlock-Lomax | Shampoo compositions |
WO1992004882A1 (en) * | 1990-09-21 | 1992-04-02 | The Procter & Gamble Company | Mild shampoo compositions |
-
1993
- 1993-10-22 SE SE9303481A patent/SE9303481L/en not_active Application Discontinuation
-
1994
- 1994-10-17 WO PCT/EP1994/003432 patent/WO1995011004A1/en not_active Application Discontinuation
- 1994-10-17 EP EP94930961A patent/EP0737061A1/en not_active Withdrawn
- 1994-10-17 JP JP7511325A patent/JPH09504017A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0127580A2 (en) * | 1983-05-31 | 1984-12-05 | Ciba-Geigy Ag | Mixtures of quaternary polymeric ammonium salts and of a ternary surfactant system based on non ionic, anionic and amphoteric surfactants, its preparation and its use in cosmetic compositions |
EP0160507A2 (en) * | 1984-04-25 | 1985-11-06 | Eric Graham Fishlock-Lomax | Shampoo compositions |
WO1992004882A1 (en) * | 1990-09-21 | 1992-04-02 | The Procter & Gamble Company | Mild shampoo compositions |
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869441A (en) * | 1997-06-05 | 1999-02-09 | Lever Brothers Company, Division Of Conopco, Inc. | Bar compositions comprising novel chelating surfactants |
US5801139A (en) * | 1997-06-05 | 1998-09-01 | Lever Brothers Company, Division Of Conopco, Inc. | Process for making bar compositions comprising novel chelating surfactants |
DE10150410A1 (en) * | 2001-08-10 | 2003-02-27 | Beiersdorf Ag | Cosmetic cleaning preparations based on a combination of sodium laureth sulfate and alkyl polyamphopolycarboxylglycinates |
US9006487B2 (en) | 2005-06-15 | 2015-04-14 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
US10844028B2 (en) | 2008-11-07 | 2020-11-24 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US8969353B2 (en) | 2008-11-07 | 2015-03-03 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US8450298B2 (en) | 2008-11-07 | 2013-05-28 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US11414393B2 (en) | 2008-11-07 | 2022-08-16 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US10189802B2 (en) | 2008-11-07 | 2019-01-29 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US9556110B2 (en) | 2008-11-07 | 2017-01-31 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US10576166B2 (en) | 2009-12-01 | 2020-03-03 | Translate Bio, Inc. | Liver specific delivery of messenger RNA |
US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
US10933139B2 (en) | 2011-03-28 | 2021-03-02 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
US10117934B2 (en) | 2011-03-28 | 2018-11-06 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
US11338044B2 (en) | 2011-06-08 | 2022-05-24 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US10238754B2 (en) | 2011-06-08 | 2019-03-26 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11052159B2 (en) | 2011-06-08 | 2021-07-06 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11951181B2 (en) | 2011-06-08 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11951180B2 (en) | 2011-06-08 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US10888626B2 (en) | 2011-06-08 | 2021-01-12 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US10507249B2 (en) | 2011-06-08 | 2019-12-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11730825B2 (en) | 2011-06-08 | 2023-08-22 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11951179B2 (en) | 2011-06-08 | 2024-04-09 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US11185595B2 (en) | 2011-06-08 | 2021-11-30 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US11547764B2 (en) | 2011-06-08 | 2023-01-10 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for MRNA delivery |
US10413618B2 (en) | 2011-06-08 | 2019-09-17 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US10350303B1 (en) | 2011-06-08 | 2019-07-16 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US9597413B2 (en) | 2011-06-08 | 2017-03-21 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mRNA |
US11291734B2 (en) | 2011-06-08 | 2022-04-05 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
US9308281B2 (en) | 2011-06-08 | 2016-04-12 | Shire Human Genetic Therapies, Inc. | MRNA therapy for Fabry disease |
US11254936B2 (en) | 2012-06-08 | 2022-02-22 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
US9439968B2 (en) | 2012-08-13 | 2016-09-13 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
US9227917B2 (en) | 2012-08-13 | 2016-01-05 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
US11510937B2 (en) | 2013-03-14 | 2022-11-29 | Translate Bio, Inc. | CFTR MRNA compositions and related methods and uses |
US10420791B2 (en) | 2013-03-14 | 2019-09-24 | Translate Bio, Inc. | CFTR MRNA compositions and related methods and uses |
US11692189B2 (en) | 2013-03-14 | 2023-07-04 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US11820977B2 (en) | 2013-03-14 | 2023-11-21 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US9181321B2 (en) | 2013-03-14 | 2015-11-10 | Shire Human Genetic Therapies, Inc. | CFTR mRNA compositions and related methods and uses |
US10876104B2 (en) | 2013-03-14 | 2020-12-29 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US9957499B2 (en) | 2013-03-14 | 2018-05-01 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US9713626B2 (en) | 2013-03-14 | 2017-07-25 | Rana Therapeutics, Inc. | CFTR mRNA compositions and related methods and uses |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
US9629804B2 (en) | 2013-10-22 | 2017-04-25 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger RNA |
US10052284B2 (en) | 2013-10-22 | 2018-08-21 | Translate Bio, Inc. | Lipid formulations for delivery of messenger RNA |
US9522176B2 (en) | 2013-10-22 | 2016-12-20 | Shire Human Genetic Therapies, Inc. | MRNA therapy for phenylketonuria |
US11890377B2 (en) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc. | Lipid formulations for delivery of messenger RNA |
US10959953B2 (en) | 2013-10-22 | 2021-03-30 | Translate Bio, Inc. | Lipid formulations for delivery of messenger RNA |
US10208295B2 (en) | 2013-10-22 | 2019-02-19 | Translate Bio, Inc. | MRNA therapy for phenylketonuria |
US11377642B2 (en) | 2013-10-22 | 2022-07-05 | Translate Bio, Inc. | mRNA therapy for phenylketonuria |
US10493031B2 (en) | 2013-10-22 | 2019-12-03 | Translate Bio, Inc. | Lipid formulations for delivery of messenger RNA |
US11224642B2 (en) | 2013-10-22 | 2022-01-18 | Translate Bio, Inc. | MRNA therapy for argininosuccinate synthetase deficiency |
US11884692B2 (en) | 2014-04-25 | 2024-01-30 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US11059841B2 (en) | 2014-04-25 | 2021-07-13 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US10155785B2 (en) | 2014-04-25 | 2018-12-18 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US9850269B2 (en) | 2014-04-25 | 2017-12-26 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US10286083B2 (en) | 2014-05-30 | 2019-05-14 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
US10493166B2 (en) | 2014-05-30 | 2019-12-03 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
US11433144B2 (en) | 2014-05-30 | 2022-09-06 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
US10293057B2 (en) | 2014-05-30 | 2019-05-21 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
US10022455B2 (en) | 2014-05-30 | 2018-07-17 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
US10286082B2 (en) | 2014-05-30 | 2019-05-14 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
US10912844B2 (en) | 2014-05-30 | 2021-02-09 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
US11104652B2 (en) | 2014-06-24 | 2021-08-31 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
US10138213B2 (en) | 2014-06-24 | 2018-11-27 | Translate Bio, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
US11253605B2 (en) | 2017-02-27 | 2022-02-22 | Translate Bio, Inc. | Codon-optimized CFTR MRNA |
US11173190B2 (en) | 2017-05-16 | 2021-11-16 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR |
US11174500B2 (en) | 2018-08-24 | 2021-11-16 | Translate Bio, Inc. | Methods for purification of messenger RNA |
Also Published As
Publication number | Publication date |
---|---|
EP0737061A1 (en) | 1996-10-16 |
SE9303481D0 (en) | 1993-10-22 |
SE9303481L (en) | 1995-04-23 |
JPH09504017A (en) | 1997-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995011004A1 (en) | A personal care composition | |
FI81605C (en) | SKUMBILDANDE EMULSIONSPRODUKT FOER HUDRENING. | |
US7749523B2 (en) | Emollient skin conditioning cream and method | |
KR970001645B1 (en) | Hair shampoo | |
US4867971A (en) | Low pH shampoo containing climbazole | |
US5002680A (en) | Mild skin cleansing aerosol mousse with skin feel and moisturization benefits | |
WO1996021424A2 (en) | Mild cold pearlizing concentrates | |
JP2003246713A (en) | Method for preparing normal-temperature pearlescentized concentrate | |
JPWO2006030990A1 (en) | Cleaning composition | |
JPH01168612A (en) | Liquid detergent composition | |
JPH11189788A (en) | Transparent gel-like detergent composition | |
JPH01178596A (en) | Detergent composition | |
CN100408019C (en) | Abluent composition | |
JP4982018B2 (en) | Cleaning composition | |
JPH01168613A (en) | Detergent composition | |
JPH03255021A (en) | Liquid skin cleaning agent composition | |
JPH04198125A (en) | Detergent composition | |
WO1995001153A1 (en) | Shampoo compositions | |
US20060018865A1 (en) | Foaming cleansing composition | |
JP3130373B2 (en) | Detergent composition | |
JPH05504576A (en) | cosmetic cleansing agent | |
JPH0816240B2 (en) | Liquid detergent composition having a pearl-like appearance | |
CA2022068A1 (en) | Balanced neutral liquid detergent/lotion emulsion formulation | |
JPS59117598A (en) | Creamy detergent | |
JPS5918440B2 (en) | cleaning composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): FI JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1996 632462 Date of ref document: 19960419 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994930961 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994930961 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994930961 Country of ref document: EP |